Zoetis Inc. (NYSE:ZTS) Position Boosted by Ethic Inc.

Ethic Inc. lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 4.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 45,458 shares of the company's stock after buying an additional 2,106 shares during the period. Ethic Inc.'s holdings in Zoetis were worth $7,406,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. JPMorgan Chase & Co. lifted its holdings in shares of Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock worth $569,834,000 after acquiring an additional 279,092 shares during the last quarter. Baker Tilly Wealth Management LLC raised its position in Zoetis by 20.6% in the fourth quarter. Baker Tilly Wealth Management LLC now owns 2,080 shares of the company's stock worth $339,000 after acquiring an additional 356 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Zoetis by 64.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 409,703 shares of the company's stock worth $66,753,000 after purchasing an additional 160,826 shares in the last quarter. Franklin Street Advisors Inc. NC grew its stake in shares of Zoetis by 2.9% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 98,641 shares of the company's stock worth $16,072,000 after buying an additional 2,786 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its stake in shares of Zoetis by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 9,569 shares of the company's stock worth $1,559,000 after acquiring an additional 234 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Piper Sandler increased their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus dropped their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Zoetis currently has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Stock Down 0.9%

Shares of NYSE:ZTS traded down $1.49 during midday trading on Tuesday, hitting $160.43. 3,336,674 shares of the company's stock were exchanged, compared to its average volume of 2,501,661. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market cap of $71.58 billion, a PE ratio of 29.33, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The stock has a 50 day moving average price of $157.17 and a 200-day moving average price of $165.83. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.38 earnings per share. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.